These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 6439455)

  • 1. Single-dose model for predicting steady-state valproic acid serum concentrations in seizure patients.
    Pugh CB; Garnett WR; Poynor WJ; Pellock JM
    Clin Pharm; 1984; 3(6):643-9. PubMed ID: 6439455
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prediction of steady-state concentrations of valproic acid as determined from single plasma concentrations after the first dose.
    May CA; Garnett WR
    Clin Pharm; 1983; 2(2):143-7. PubMed ID: 6411412
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetic parameters of total and unbound valproic acid and their relationships to seizure control in epileptic children.
    Panomvana Na Ayudhya D; Suwanmanee J; Visudtibhan A
    Am J Ther; 2006; 13(3):211-7. PubMed ID: 16772762
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inverse correlation of valproic acid serum concentrations and quality of life in adolescents with epilepsy.
    Jakovljevic MB; Jankovic SM; Jankovic SV; Todorovic N
    Epilepsy Res; 2008 Aug; 80(2-3):180-3. PubMed ID: 18495431
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Single dose and steady state pharmacokinetics of valproic acid in adult epileptic patients.
    Miljković B; Pokrajac M; Varagić V; Lević Z
    Int J Clin Pharmacol Res; 1991; 11(3):137-41. PubMed ID: 1809700
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interactions of serum albumin, valproic acid and carbamazepine with the pharmacokinetics of phenytoin in cancer patients.
    Joerger M; Huitema AD; Boogerd W; van der Sande JJ; Schellens JH; Beijnen JH
    Basic Clin Pharmacol Toxicol; 2006 Aug; 99(2):133-40. PubMed ID: 16918714
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Problems in serum-level determination during valproic acid therapy].
    Schäfer H; Reith H; Jacobs R; Gabriel KH
    Arzneimittelforschung; 1977; 27(6):1215-21. PubMed ID: 332187
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High unbound fraction of valproic acid in a hypoalbuminemic critically ill patient on renal replacement therapy.
    de Maat MM; van Leeuwen HJ; Edelbroek PM
    Ann Pharmacother; 2011 Mar; 45(3):e18. PubMed ID: 21325101
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetic study of valproic acid in a neonate.
    Irvine-Meek JM; Hall KW; Otten NH; Leroux M; Budnik D; Seshia SS
    Pediatr Pharmacol (New York); 1982; 2(4):317-21. PubMed ID: 6821439
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Different serum concentrations of steady-state valproic acid in two sustained-release formulations.
    Yasui-Furukori N; Saito M; Nakagami T; Niioka T; Sato Y; Fujii A; Kaneko S
    Psychiatry Clin Neurosci; 2007 Jun; 61(3):308-12. PubMed ID: 17472600
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetic variability of nimodipine disposition after single and multiple oral dosing to hypertensive renal failure patients: parametric and nonparametric population analysis.
    Terziivanov D; Atanasova I; Dimitrova V; Robeva R; Unger S; Mück W
    Int J Clin Pharmacol Ther; 1999 Aug; 37(8):404-12. PubMed ID: 10475143
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rufinamide: clinical pharmacokinetics and concentration-response relationships in patients with epilepsy.
    Perucca E; Cloyd J; Critchley D; Fuseau E
    Epilepsia; 2008 Jul; 49(7):1123-41. PubMed ID: 18503564
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nonparametric population modeling of valproate pharmacokinetics in epileptic patients using routine serum monitoring data: implications for dosage.
    Bondareva IB; Jelliffe RW; Sokolov AV; Tischenkova IF
    J Clin Pharm Ther; 2004 Apr; 29(2):105-20. PubMed ID: 15068399
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Steady-state valproate pharmacokinetics during long term therapy.
    Eadie MJ; Heazlewood V; McKauge L; Tyrer JH
    Clin Exp Neurol; 1983; 19():183-91. PubMed ID: 6439443
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Can the serum protein binding of valproic acid limit the hepatic elimination?
    Kodama Y; Kuranari M; Teraoka I; Fujii I; Takeyama M
    Int J Clin Pharmacol Ther Toxicol; 1993 Nov; 31(11):529-32. PubMed ID: 8294164
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Acute seizures due to a probable interaction between valproic acid and meropenem.
    Coves-Orts FJ; Borrás-Blasco J; Navarro-Ruiz A; Murcia-López A; Palacios-Ortega F
    Ann Pharmacother; 2005 Mar; 39(3):533-7. PubMed ID: 15701769
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Valproic acid poisoning: an evidence-based consensus guideline for out-of-hospital management.
    Manoguerra AS; Erdman AR; Woolf AD; Chyka PA; Caravati EM; Scharman EJ; Booze LL; Christianson G; Nelson LS; Cobaugh DJ; Troutman WG;
    Clin Toxicol (Phila); 2008 Aug; 46(7):661-76. PubMed ID: 18608263
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Individualizing phenobarbital dosing in neonates.
    Gilman ME; Toback JW; Gal P; Erkan NV
    Clin Pharm; 1983; 2(3):258-62. PubMed ID: 6883954
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effects of neuroleptics (haloperidol and chlorpromazine) on the pharmacokinetics of valproic acid in schizophrenic patients.
    Ishizaki T; Chiba K; Saito M; Kobayashi K; Iizuka R
    J Clin Psychopharmacol; 1984 Oct; 4(5):254-61. PubMed ID: 6149238
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetic modeling of valproate from clinical data in Serbian epileptic patients.
    Jankovic SM; Milovanovic JR
    Methods Find Exp Clin Pharmacol; 2007 Dec; 29(10):673-9. PubMed ID: 18200330
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.